KalVista Pharmaceuticals (STU:4XC1) Accounts Payable & Accrued Expense : €11.45 Mil (As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Accounts Payable & Accrued Expense?

KalVista Pharmaceuticals's quarterly accounts payable & accrued expense increased from Jul. 2023 (€9.50 Mil) to Oct. 2023 (€12.07 Mil) but then declined from Oct. 2023 (€12.07 Mil) to Jan. 2024 (€11.45 Mil).

KalVista Pharmaceuticals's annual accounts payable & accrued expense increased from Apr. 2021 (€4.52 Mil) to Apr. 2022 (€5.96 Mil) and increased from Apr. 2022 (€5.96 Mil) to Apr. 2023 (€8.88 Mil).

KalVista Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for KalVista Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Accounts Payable & Accrued Expense Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.84

4.42

4.52

5.96

8.88

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															5.97	8.88	9.50	12.07	11.45

KalVista Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines